GSK (NYSE:GSK) Cut to “Hold” at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft downgraded shares of GSK (NYSE:GSK) from a buy rating to a hold rating in a research note published on Friday morning, MarketBeat Ratings reports.

Several other equities analysts have also weighed in on GSK. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their target price for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Argus raised GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, Barclays upgraded GSK to a “hold” rating in a report on Tuesday, August 27th. Seven analysts have rated the stock with a hold rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Trading Down 3.0 %

NYSE GSK opened at $33.35 on Friday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. GSK has a one year low of $32.83 and a one year high of $45.92. The company’s 50 day moving average price is $39.08 and its 200 day moving average price is $40.68. The firm has a market capitalization of $69.12 billion, a price-to-earnings ratio of 21.66, a PEG ratio of 1.29 and a beta of 0.66.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be paid a $0.3928 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.71%. GSK’s payout ratio is 98.70%.

Insider Buying and Selling at GSK

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of GSK stock in a transaction on Friday, September 27th. The shares were purchased at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. The trade was a 19.97 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.00% of the stock is owned by insiders.

Institutional Investors Weigh In On GSK

A number of institutional investors have recently modified their holdings of GSK. SG Americas Securities LLC raised its stake in GSK by 448.7% during the first quarter. SG Americas Securities LLC now owns 17,690 shares of the pharmaceutical company’s stock valued at $758,000 after buying an additional 14,466 shares in the last quarter. Kingsview Wealth Management LLC boosted its holdings in GSK by 3.4% in the first quarter. Kingsview Wealth Management LLC now owns 17,276 shares of the pharmaceutical company’s stock worth $741,000 after purchasing an additional 563 shares during the period. Blair William & Co. IL increased its stake in GSK by 14.9% during the first quarter. Blair William & Co. IL now owns 23,493 shares of the pharmaceutical company’s stock valued at $1,007,000 after purchasing an additional 3,044 shares during the last quarter. Nwam LLC raised its holdings in shares of GSK by 126.4% during the first quarter. Nwam LLC now owns 16,080 shares of the pharmaceutical company’s stock worth $710,000 after purchasing an additional 8,976 shares during the period. Finally, TIAA Trust National Association bought a new position in shares of GSK in the 1st quarter worth about $302,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.